• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Obese Nonvalvular Atrial Fibrillation Patients: Analysis of Electronic Health Record Data.
Conclusions: Among obese NVAF patients, prescription of rivaroxaban was associated with a reduced risk of SSE and major bleeding compared to warfarin, which remained consistent across BMI classes. PMID: 32347755 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 1, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
CONCLUSION: This study demonstrated the value of supplementing longitudinal site-based clinical studies with administrative claims data. Our results suggest that claims data together with network partner electronic health record data constitute an effective vehicle to capture patient outcomes since >30% of patients have non-fatal and fatal events outside of enrolling sites. PMID: 31081367 [PubMed - as supplied by publisher]
Source: Clinical Trials - May 12, 2019 Category: Research Authors: Ma Q, Chung H, Shambhu S, Roe M, Cziraky M, Jones WS, Haynes K Tags: Clin Trials Source Type: research

Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
CONCLUSIONS: Our observational data from clinical practice broadly confirm the safety and efficacy results of pivotal randomized controlled trials of apixaban for stroke prevention among NVAF patients. PMID: 29772946 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 19, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.
CONCLUSIONS: Ischemic stroke rates were significantly lower in the overall NVAF population for rivaroxaban vs warfarin users, including patients with eCrCl below 50 mL/min. For all renal function groups, major bleeding risks were not statistically different between treatment groups. PMID: 28590785 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 8, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research